Journals / Turkish Neurosurgery / 2018 / Cilt: 28 - Sayı: 6

Benign-appearing Intraspinal Malignant Peripheral Nerve Sheath Tumors: Treatments and Outcomes of 14 Consecutive Patients

Pages
983–988
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The present study found that age at diagnosis, Neurofibromatosis type 1 (NF-1) history, tumor sites,malignant grade, Ki-67 and tumor resection method might be factors closely associated with recurrence and survival of intraspinalMPNSTs patients.CONCLUSION: Benign-appearing intraspinal MPNSTs are relatively rare tumors with a better overall prognosis compared withcommon spinal MPNSTs.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIM: To investigate the clinical characteristics and prognostic factors that may influence outcomes of patients undergoing benignappearing intraspinal malignant peripheral nerve sheath tumors (MPNSTs).MATERIAL and METHODS: This study included a total of 14 consecutive patients who were diagnosed with benign intraspinaltumors firstly and confirmed as intraspinal MPNSTs by pathology.
📊
Key Findings & Data:The survival rate was estimatedusing the Kaplan–Meier method, and differences were analyzed by carrying out the log-rank test.
💡
Conclusion & Impact:The present study found that age at diagnosis, Neurofibromatosis type 1 (NF-1) history, tumor sites,malignant grade, Ki-67 and tumor resection method might be factors closely associated with recurrence and survival of intraspinalMPNSTs patients.CONCLUSION: Benign-appearing intraspinal MPNSTs are relatively rare tumors with a better overall prognosis compared withcommon spinal MPNSTs.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

AIM: To investigate the clinical characteristics and prognostic factors that may influence outcomes of patients undergoing benignappearing intraspinal malignant peripheral nerve sheath tumors (MPNSTs).MATERIAL and METHODS: This study included a total of 14 consecutive patients who were diagnosed with benign intraspinaltumors firstly and confirmed as intraspinal MPNSTs by pathology. The univariate analyses of various clinical factors were performedto identify variables that could predict prognosis. Endpoints were mortality and local recurrence. The survival rate was estimatedusing the Kaplan–Meier method, and differences were analyzed by carrying out the log-rank test. In addition, factors with p valuesof ≤0.05 were considered statistically significant.RESULTS: Benign-appearing intraspinal MPNSTs showed some different clinical features compared with spinal MPNSTs andintraspinal benign tumors. The present study found that age at diagnosis, Neurofibromatosis type 1 (NF-1) history, tumor sites,malignant grade, Ki-67 and tumor resection method might be factors closely associated with recurrence and survival of intraspinalMPNSTs patients.CONCLUSION: Benign-appearing intraspinal MPNSTs are relatively rare tumors with a better overall prognosis compared withcommon spinal MPNSTs. A lot of factors can affect patients’ survival and local recurrence. These prognostic factors still requirefurther confirmation with further studies including more patients.

🔖

Cite This Article

GONG, H., ZHANG, D., WANG, D., HE, S., YANG, X., WEI, H., XIAO, J. (2018). Benign-appearing Intraspinal Malignant Peripheral Nerve Sheath Tumors: Treatments and Outcomes of 14 Consecutive Patients. Turkish Neurosurgery, Cilt: 28 - Sayı: 6, 983–988. https://ajindex.com/articles/417670

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Ailon T, Torabi R, Fisher CG, Rhines LD, Clarke MJ, Bettegowda C, Boriani S, Yamada YJ, Kawahara N, Varga PP, Shin JH, Saghal A, Gokaslan ZL: Management of locally recurrent chordoma of the mobile spine and sacrum: A systematic review. Spine 41 Suppl 20:S193-S198, 2016
  2. Ali HS, Endo T, Endo H, Murakami K, Tominaga T: Intraspinal dissemination of intracranial hemangiopericytoma: Case report and literature review. Surg Neurol Int 7:S1016-S1020, 2016
  3. Anghileri M, Miceli R, Fiore M, Mariani L, Ferrari A, Mussi C, Lozza L, Collini P, Olmi P, Casali PG, Pilotti S, Gronchi A: Malignant peripheral nerve sheath tumors: Prognostic factors and survival in a series of patients treated at a single institution. Cancer 107:1065-1074, 2006
  4. Charest-Morin R, Fisher CG, Varga PP, Gokaslan ZL, Rhines LD, Reynolds JJ, Dekutoski MB, Quraishi NA, Bilsky MH, Fehlings MG, Chou D, Germscheid NM, Luzzati A, Boriani S, Tumor AOKF: En bloc resection versus intralesional surgery in the treatment of giant cell tumor of the spine. Spine 42(18):1383-1390, 2017
  5. Chou D, Bilsky MH, Luzzati A, Fisher CG, Gokaslan ZL, Rhines LD, Dekutoski MB, Fehlings MG, Ghag R, Varga P, Boriani S, Germscheid NM, Reynolds JJ, Tumor AOKF: Malignant peripheral nerve sheath tumors of the spine: Results of surgical management from a multicenter study. J Neurosurg Spine 26:291-298, 2017
  6. Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM: Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 57:2006-2021, 1986
  7. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710-1715, 1984
  8. Gerdes J, Pileri S, Bartels H, Stein H: Proliferation marker Ki-67: Correlation with histological diagnosis, neoplasm grading and clinical course. Verhandlungen der Deutschen Gesellschaft fur Pathologie 70:152-158, 1986 (In German) Grobmyer SR, Reith JD, Shahlaee A, Bush CH, Hochwald SN: Malignant peripheral nerve sheath tumor: Molecular pathogenesis and current management considerations. J Surg Oncol 97:340-349, 2008
  9. Gupta G, Maniker A: Malignant peripheral nerve sheath tumors. Neurosurg Focus 22:E12, 2007
  10. Hwang IK, Hahn SM, Kim HS, Kim SK, Kim HS, Shin KH, Suh CO, Lyu CJ, Han JW: Outcomes of treatment for malignant peripheral nerve sheath tumors: Different clinical features associated with neurofibromatosis type 1. Cancer Res Treat 49(3):717-726, 2017 Kolbe